FDA approves Trulance from Synergy Pharmaceuticals
The Food and Drug Administration has approved Synergy Pharmaceuticals’s Trulance (plecanatide), the company and agency announced Thursday. The drug is indicated to treat adults with chronic idiopathic constipation. It’s the first drug designed to replicate the function of the gastrointestinal peptide uroguanylin.
“We are thrilled with the approval of Trulance because it provides an additional, much-needed, new treatment option to help adults with chronic idiopathic constipation and their healthcare providers manage this condition,” Synergy Pharmaceuticals chairman and CEO Gary Jacobs said. “I am confident that we truly have the right team with the right strategic vision and the right launch plan to successfully bring Trulance into this large but underserved market.”The company said Trulance would be available later this quarter.
January 20, 2017 | By David Salazar